Cervical dysplasia is the presence of abnormal cells on the surface of the cervix. These cells are not cancer, but depending on their severity, they can progress to cervical cancer over time if left untreated. Nearly all cases are caused by persistent infection with certain strains of human papillomavirus (HPV), and the condition is almost always detected through routine screening rather than symptoms.
How Cervical Dysplasia Is Graded
The cervix is lined with a thin layer of cells called the epithelium. Dysplasia is graded by how much of that cell layer is affected, using a system called cervical intraepithelial neoplasia, or CIN.
- CIN 1 (low grade): Abnormal cells are found only in the lower third of the epithelium. This is the mildest form and often resolves on its own.
- CIN 2 (high grade): Abnormal cells extend beyond the lower third but haven’t replaced the full thickness of the lining.
- CIN 3 (high grade): Abnormal cells span the entire thickness of the epithelium. This is the most severe form of dysplasia before cancer.
The key distinction between dysplasia and cancer is a boundary called the basement membrane. As long as abnormal cells stay above it, the condition is precancerous. When cells break through that boundary, it becomes invasive cervical cancer.
The Role of HPV
Twelve strains of HPV are classified as high risk for causing cervical changes. Two of them, HPV 16 and HPV 18, are responsible for most HPV-related cancers. Most HPV infections clear on their own within a year or two, but when a high-risk strain persists, it can trigger the cell changes that lead to dysplasia.
Several factors make it more likely that an HPV infection will stick around and progress. A weakened immune system, whether from HIV, organ transplant medications, or autoimmune treatments, reduces your body’s ability to clear the virus. Smoking and even regular exposure to secondhand smoke increase the risk, and that risk rises the more you smoke. Obesity can also play an indirect role by making cervical screening less effective, which lowers detection of early cell changes. Long-term use of oral contraceptives has been associated with higher risk as well, though the reasons aren’t fully understood.
Symptoms (or Lack of Them)
Cervical dysplasia rarely causes symptoms. Some people experience irregular vaginal bleeding or spotting after intercourse, but most find out they have it only after a routine Pap smear comes back abnormal. This is why regular cervical screening matters so much. Without it, dysplasia can progress silently.
How It’s Diagnosed
Diagnosis typically follows a stepwise process that starts with screening results. A Pap smear may show low-grade or high-grade squamous cell changes, and an HPV test may detect a high-risk strain. What happens next depends on the severity of those results.
Low-grade findings, like mild cell changes with a negative HPV test, don’t usually require immediate follow-up beyond repeating the Pap smear the following year. If the abnormality persists or the HPV test is positive, the next step is colposcopy: a procedure where a doctor uses a lighted magnifying instrument to examine the cervix closely. During colposcopy, any suspicious-looking areas are biopsied, and those tissue samples provide the definitive diagnosis and CIN grade.
High-grade findings on a Pap smear prompt immediate colposcopy because of the possibility that more advanced dysplasia or even early cancer could be present.
Does It Go Away on Its Own?
It can, especially for lower-grade changes. In a study of women under 25 with high-grade lesions who were monitored rather than immediately treated, 88% of those with CIN 2 saw their dysplasia regress, with 76% experiencing complete regression back to normal tissue. CIN 3 behaved differently: only about 29% regressed, while 71% persisted without progressing. No patients in the study developed invasive cancer during the observation period.
Timing matters too. Among CIN 2 cases, about 62% regressed within two years. For CIN 3, only about 20% improved within two years, and roughly 25% within three. Smoking also made a difference: spontaneous regression occurred in about 39% of smokers compared to 46% of nonsmokers.
These numbers explain why doctors often recommend a “watch and wait” approach for CIN 1 and sometimes CIN 2, particularly in younger patients, while CIN 3 is more likely to require treatment.
Treatment Options
When treatment is needed, the two most common procedures are LEEP (loop electrosurgical excision procedure) and cold knife conization. Both remove the abnormal area of cervical tissue, but they differ in important ways.
LEEP uses a thin heated wire loop to remove tissue. It’s typically done in an outpatient clinic under local anesthesia and costs less. Cold knife conization is a surgical procedure usually performed under general or regional anesthesia in a hospital. It removes a cone-shaped piece of tissue and has traditionally been used for more complex or severe cases.
In terms of outcomes, both procedures have similar rates of residual disease (about 9% for LEEP and 11% for cold knife conization) and similar recurrence rates (around 7% and 6%, respectively). Where they differ is in how cleanly they remove tissue at the edges: LEEP leaves positive margins (meaning abnormal cells at the cut edge) about 44% of the time, compared to 29% for cold knife conization. Positive margins don’t always mean the dysplasia will come back, but they do require closer monitoring.
For people who plan to become pregnant in the future, LEEP carries a lower risk of preterm delivery. One large trial found preterm delivery rates of 5% after LEEP versus 11% after cold knife conization.
Follow-Up After Treatment
After treatment for abnormal cervical cells, you’ll typically be invited back for a follow-up screening test about six months later. This test includes HPV testing. If no HPV is found, you won’t need another screening for three years. If HPV is detected or cell changes remain, you’ll return to colposcopy to determine whether additional treatment is needed.
How the HPV Vaccine Helps
The HPV vaccine is the most effective way to prevent cervical dysplasia from developing in the first place. A large Cochrane review found that girls vaccinated before age 16 were 80% less likely to develop cervical cancer than unvaccinated girls. The vaccines also substantially reduced precancerous changes (CIN 2 and CIN 3) and the number of people needing treatment for HPV-related disease in those vaccinated between ages 15 and 25.
The vaccine works best when given before exposure to HPV, which is why it’s recommended in early adolescence. But even for those vaccinated later, it still provides significant protection against strains they haven’t yet encountered.